Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05630196 | A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain | PHASE2 | COMPLETED | 138 | — | — | Dec 8, 2022 | Jun 15, 2023 | Aug 13, 2024 | 30 | United States, Puerto Rico |
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. The data presented are the posterior mean with a 95% credible interval.
| Arm | Type | Description |
|---|---|---|
| LY3857210 | EXPERIMENTAL | Participants received 45 milligrams (mg) of LY3857210 orally once daily for up to 8 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo orally once daily for up to 8 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3857210 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have a visual analog scale (VAS) pain value ≥40 and \<95 during screening. * Have a history of daily pain for at least 12 weeks based on participant report or medical history. * Have a body mass index \<40 kilograms per meter squared (kg/m²) (inclusive). * Are willing to maint...